EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Protein kinase B inhibitors enhance the sensitivity of translocated promoter region–fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis

Mengyao Lv, Wenbing Shangguan, Qian Zhao, Yan Li, Quan Zhao, Feng Li iD

Journal of International Medical Research · 2025

DOI: 10.1177/03000605251362968 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of International Medical Research, 2025. Verfasst von Mengyao Lv und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, China. Hauptthemen laut MEDLINE: Apoptosis, Receptor, Fibroblast Growth Factor, Type 1, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Jinling Hospital of Nanjing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Fibroblast growth factor receptor 1 (FGFR1) inhibitors are considered effective for treating 8p11 myeloproliferative syndrome. However, targeting FGFR1 alone may be inadequate for patients with translocated promoter region (TPR)–FGFR1 rearrangement.

Methods

In this study, we established TPR–FGFR1-expressing BaF3 cells and performed RNA sequencing analysis. Then, western blot analysis was performed to evaluate the protein expression levels of FGFR1 and phosphorylation of protein kinase B. Furthermore, flow cytometric analysis (fluorescence-activated cell sorting) was used to assess apoptosis levels.

Results

RNA sequencing analysis revealed that TPR–FGFR1-related genes are mainly involved in the epidermal growth factor receptor pathway. Gene set enrichment analysis highlighted the enrichment of genes in the phosphoinositide 3-kinase/protein kinase B pathway. FGFR1 inhibitor alone inhibited the phosphorylation of FGFR1 but not that of downstream protein kinase B. Combined FGFR1 inhibitor and protein kinase B inhibitor treatment simultaneously suppressed FGFR1 and protein kinase B phosphorylation. Fluorescence-activated cell sorting showed that combination therapy significantly increased apoptosis levels compared with FGFR1 inhibitor monotherapy.

Conclusions

We found that epidermal growth factor receptor is another activation mechanism of the protein kinase B pathway in TPR–FGFR1-expressing BaF3 cells. Furthermore, co-treatment with FGFR1 inhibitor and protein kinase B inhibitor inhibited the phosphorylation of FGFR1 and protein kinase B. Dual FGFR1 and protein kinase B inhibition enhances apoptosis, supporting dual targeting therapy for TPR–FGFR1-rearranged 8p11 myeloproliferative syndrome, offering a novel treatment direction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisReceptor, Fibroblast Growth Factor, Type 1Protein Kinase InhibitorsProto-Oncogene Proteins c-aktHumansPromoter Regions, GeneticPhosphorylationMiceAnimalsSignal TransductionCell Line, TumorTranslocation, Genetic

Stichwörter der Autor:innen

8p11 myeloproliferative syndromecombination therapyfibroblast growth factor receptor 1protein kinase B inhibitorstyrosine kinase inhibitors

Substanzen

Receptor, Fibroblast Growth Factor, Type 1Protein Kinase InhibitorsProto-Oncogene Proteins c-aktFGFR1 protein, human

Autor:innen und Institutionen

  • Department of Hematology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, China.
  • The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, China.
  • College of Food and Bioengineering, Bengbu University, China.
  • The First School of Clinical Medicine, Southern Medical University, China.
  • Department of Hematology, Jinling Hospital, Affiliated Hospital of Medical School, State Key Laboratory of Analytical Chemistry for Life Science, Medical School of Nanjing University, China.

ORCID-Profile: Feng Li

Förderung

  • Jinling Hospital of Nanjing

Zitieren

APA

Lv, M., Shangguan, W., Zhao, Q., Li, Y., Zhao, Q., & Li, F. (2025). Protein kinase B inhibitors enhance the sensitivity of translocated promoter region–fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis. Journal of International Medical Research. https://doi.org/10.1177/03000605251362968

Vancouver

Lv M, Shangguan W, Zhao Q, Li Y, Zhao Q, Li F. Protein kinase B inhibitors enhance the sensitivity of translocated promoter region–fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis. Journal of International Medical Research. 2025. doi:10.1177/03000605251362968

BibTeX
@article{Lv2025,
  author = {Lv, Mengyao and Shangguan, Wenbing and Zhao, Qian and Li, Yan and Zhao, Quan and Li, Feng},
  title = {Protein kinase B inhibitors enhance the sensitivity of translocated promoter region–fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis},
  journal = {Journal of International Medical Research},
  year = {2025},
  doi = {10.1177/03000605251362968}
}
Kostenlos starten →